Pharming Group to convene Extraordinary General Meeting of Shareholders
22 January 2025 - 4:00AM
UK Regulatory
Pharming Group to convene Extraordinary General Meeting of
Shareholders
Leiden, the Netherlands, January 21,
2025: Pharming Group N.V. (“Pharming” or “the
Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces it
will hold an Extraordinary General Meeting of Shareholders (EGM) on
March 4, 2025, at 14:00 CET. The Notice to Convene, Explanatory
Notes, Voting information, meeting documents and Form of Proxy can
be found on the Company’s website under Investors/Shareholder
Meetings.
The EGM is convened for the appointment of Mr.
Fabrice Chouraqui as Executive Director and Chief Executive Officer
for a term of four years, based on a binding nomination by the
Board of Directors. Mr. Chouraqui will be successor to Mr. Sijmen
de Vries, subject to (and therefore effective as of) his
appointment as Executive Director and Chief Executive Officer at
the EGM.
The agenda further includes the proposal to
approve certain components of the remuneration package of Mr.
Chouraqui in his capacity as Executive Director and Chief Executive
Officer. Details can be found in the Explanatory Notes for the EGM
and the summary of the remuneration package as available on the
Company’s website under Investors/Shareholder Meetings.
The EGM will be held as a physical meeting at
the Corpus Congress Centre, Willem Einthovenstraat 1, 2342 BH in
Oegstgeest, the Netherlands. Our shareholders are invited to attend
the EGM in person or to follow the meeting through our live
webcast.
About Pharming Group
N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a
global biopharmaceutical company dedicated to transforming the
lives of patients with rare, debilitating, and life-threatening
diseases. Pharming is commercializing and developing an innovative
portfolio of protein replacement therapies and precision medicines,
including small molecules and biologics. Pharming is headquartered
in Leiden, the Netherlands, and has employees around the globe who
serve patients in over 30 markets in North America, Europe, the
Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and
find us on LinkedIn.
Inside Information
This press release relates to the disclosure of information
that qualifies, or may have qualified, as inside information within
the meaning of Article 7(1) of the EU Market Abuse
Regulation.
For further public information,
contact:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate
Communications
T: +1 (908) 705 1696
E: investor@pharming.com
FTI Consulting, London, UK
Victoria Foster Mitchell/Alex Shaw/Amy Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication,
Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
- Pharming Group to convene Extraordinary General Meeting of
Shareholders_EN_21JAN25
Pharming Group NV (EU:PHARM)
Historical Stock Chart
From Dec 2024 to Jan 2025
Pharming Group NV (EU:PHARM)
Historical Stock Chart
From Jan 2024 to Jan 2025
